Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003553264 | SCV004268148 | uncertain significance | not provided | 2023-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with threonine, which is neutral and polar, at codon 40 of the POU3F4 protein (p.Ser40Thr). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with POU3F4-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004661680 | SCV005150753 | uncertain significance | Inborn genetic diseases | 2024-04-29 | criteria provided, single submitter | clinical testing | The c.119G>C (p.S40T) alteration is located in exon 1 (coding exon 1) of the POU3F4 gene. This alteration results from a G to C substitution at nucleotide position 119, causing the serine (S) at amino acid position 40 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |